

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT3138792

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	PONIARD PHARMACEUTICALS, INC.	03/12/2013
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	PONIARD (ASSIGNMENT FOR THE BENEFIT OF CREDITORS), LLC	
<b>Street Address:</b>	1100 LA AVENIDA STREET	
<b>Internal Address:</b>	BUILDING A	
<b>City:</b>	MOUNTAIN VIEW	
<b>State/Country:</b>	CALIFORNIA	
<b>Postal Code:</b>	94043	
<b>PROPERTY NUMBERS Total: 1</b>		
	<b>Property Type</b>	<b>Number</b>
	<b>Patent Number:</b>	8168661
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	312.873.3678	
<b>Email:</b>	CFINN@POLSINELLI.COM	
<b>Correspondent Name:</b>	POLSINELLI PC	
<b>Address Line 1:</b>	161 NORTH CLARK STREET	
<b>Address Line 2:</b>	SUITE 4200	
<b>Address Line 4:</b>	CHICAGO, ILLINOIS 60601	
<b>ATTORNEY DOCKET NUMBER:</b>	078554-475596	
<b>NAME OF SUBMITTER:</b>	RON GALANT, PH.D.	
<b>SIGNATURE:</b>	/Ron Galant, Ph.D./	
<b>DATE SIGNED:</b>	12/09/2014	
<b>Total Attachments: 18</b>		
source=Assignment1_Poniard_Poniardbenefitofcreditors#page1.tif		
source=Assignment1_Poniard_Poniardbenefitofcreditors#page2.tif		
source=Assignment1_Poniard_Poniardbenefitofcreditors#page3.tif		
source=Assignment1_Poniard_Poniardbenefitofcreditors#page4.tif		
source=Assignment1_Poniard_Poniardbenefitofcreditors#page5.tif		

PATENT

source=Assignment1\_Poniard\_Poniardbenefitofcreditors#page6.tif  
source=Assignment1\_Poniard\_Poniardbenefitofcreditors#page7.tif  
source=Assignment1\_Poniard\_Poniardbenefitofcreditors#page8.tif  
source=Assignment1\_Poniard\_Poniardbenefitofcreditors#page9.tif  
source=Assignment1\_Poniard\_Poniardbenefitofcreditors#page10.tif  
source=Assignment1\_Poniard\_Poniardbenefitofcreditors#page11.tif  
source=Assignment1\_Poniard\_Poniardbenefitofcreditors#page12.tif  
source=Assignment1\_Poniard\_Poniardbenefitofcreditors#page13.tif  
source=Assignment1\_Poniard\_Poniardbenefitofcreditors#page14.tif  
source=Assignment1\_Poniard\_Poniardbenefitofcreditors#page15.tif  
source=Assignment1\_Poniard\_Poniardbenefitofcreditors#page16.tif  
source=Assignment1\_Poniard\_Poniardbenefitofcreditors#page17.tif  
source=Assignment1\_Poniard\_Poniardbenefitofcreditors#page18.tif

GENERAL ASSIGNMENT FOR THE BENEFIT  
OF CREDITORS PURSUANT TO RCW 7.08.030

THIS ASSIGNMENT is made this 12<sup>th</sup> day of March, 2013, by and between Poniard Pharmaceuticals, Inc., a Washington corporation, with offices at 300 Elliott Avenue West, Suite 530, Seattle, WA 98119 (hereinafter referred to as the "Assignor"), and Poniard (assignment for the benefit of creditors), LLC a California limited liability company (hereinafter referred to as the "Assignee").

WHEREAS, the assignor has been engaged in the business of pharmaceuticals research and development, and ceased ongoing operations within the last twelve months; and

WHEREAS, the Assignor is indebted to creditors, as set forth in Schedule A annexed hereto, is unable to pay debts as they have become due, and is desirous of providing for the payment of debts, so far as it is possible, by an assignment of all property for that purpose.

NOW THEREFORE, the Assignor, in consideration of the Assignee's acceptance of this assignment, and for other good and valuable consideration, hereby grants, assigns, conveys, transfers, and sets over, unto the Assignee, and the Assignee's successors and assigns, all of the Assignor's property, except such property as is exempt by law from levy and sale under an execution (and then only to the extent of such exemption), including, but not limited to, all real property, fixtures, goods, stock, inventory, equipment, intellectual property (including patents and trademarks), furniture, furnishings, accounts receivable, general intangibles, bank deposits, cash, promissory notes, cash value and proceeds of insurance policies, claims and demands belonging to the Assignor, wherever such property may be located (hereinafter collectively the "Estate"), which property is, to the best knowledge and belief of the Assignor, fully and accurately set forth on Schedule B annexed hereto.

By making this assignment, the Assignor consents to the appointment of the Assignee as a general receiver with respect to the Assignee's property in accordance with RCW 7.60 *et seq.*

The Assignee shall take possession of and administer the estate, and shall liquidate the estate with reasonable dispatch and convert the estate into money, collect all claims and demands hereby assigned as and to the extent they may be collectible, and pay and discharge all reasonable expenses, costs, and disbursements in connection with the execution and administration of this assignment from the proceeds of such liquidation and collections.

The Assignee shall then pay and discharge in full, to the extent that funds are available in the estate after payment of administrative expenses, costs and disbursements, all of the debts and liabilities now due from the Assignor, including interest on such debts and liabilities in full, according to their priority as established by law, and on a pro rata basis within each class.

In the event that all debts and liabilities are paid in full, the remainder of the estate shall be returned to the Assignor.

To accomplish the purposes of this assignment, the Assignor hereby irrevocably appoints the Assignee as the Assignor's true and lawful attorney in fact, with full power and authority to do all acts and things which may be necessary to execute and fulfill the assignment hereby created, to the same extent as such acts and things might be done by the Assignor in the absence of this Assignment, including but not limited to the power to demand and recover from all persons all property of the estate; to sue for the recovery of such property; to execute, acknowledge, and deliver all necessary deeds, instruments, and conveyances, and to grant and convey any or all of the real or personal property of the estate pursuant thereto; and to appoint one or more attorneys to assist the Assignee in carrying out the Assignee's duties hereunder.

The Assignor hereby authorizes the Assignee to sign the name of the Assignor to any check, draft, promissory note, or other instrument in writing which is payable to the order of the Assignor, or to sign the name of the Assignor to any instrument in writing, whenever it shall be necessary to do so, to carry out the purposes of this assignment.

The Assignor declares, under penalty of perjury under the laws of the State of Washington, that the attached list of creditors and of the property of the Assignor is true and complete to the best of the Assignor's knowledge.

The Assignee hereby accepts the trust created by the foregoing assignment, and agrees faithfully and without delay to carry out the Assignee's duties under the foregoing assignment.

*Assignor:*


PONIARD PHARMACEUTICALS, INC.

By: 

Name: Fred Conves  
Its duly-authorized signatory

*Assignee:*

Poniard (assignment for the benefit of creditors), LLC



# CALIFORNIA ALL-PURPOSE ACKNOWLEDGMENT

State of California

County of

San Francisco

On

3/12/13

Date

before me,

M. A. Josephson

Here Insert Name and Title of the Officer

personally appeared

Fred Cranes

Name(s) of Signer(s)

who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.


WITNESS my hand and official seal.

Signature

M. A. Josephson

Signature of Notary Public

Place Notary Seal Above



## OPTIONAL

Though the information below is not required by law, it may prove valuable to persons relying on the document and could prevent fraudulent removal and reattachment of this form to another document.

### Description of Attached Document

Title or Type of Document: \_\_\_\_\_

Document Date: \_\_\_\_\_

Number of Pages: \_\_\_\_\_

Signer(s) Other Than Named Above: \_\_\_\_\_

### Capacity(ies) Claimed by Signer(s)

Signer's Name: \_\_\_\_\_

- ☐ Individual  
☐ Corporate Officer — Title(s): \_\_\_\_\_  
☐ Partner — ☐ Limited ☐ General  
☐ Attorney in Fact  
☐ Trustee  
☐ Guardian or Conservator  
☐ Other: \_\_\_\_\_

Signer Is Representing: \_\_\_\_\_

Signer's Name: \_\_\_\_\_

- ☐ Individual  
☐ Corporate Officer — Title(s): \_\_\_\_\_  
☐ Partner — ☐ Limited ☐ General  
☐ Attorney in Fact  
☐ Trustee  
☐ Guardian or Conservator  
☐ Other: \_\_\_\_\_

Signer Is Representing: \_\_\_\_\_

RIGHT THUMBPRINT  
OF SIGNER  
Top of thumb here

RIGHT THUMBPRINT  
OF SIGNER  
Top of thumb here

SCHEDULE A - CREDITOR LIST

1. List all creditors having security interests or liens, showing:

	<u>Name</u>	<u>Address</u>	<u>Amount</u>	<u>Collateral</u>	<u>Dispute</u>
1.	[REDACTED]				
2.	[REDACTED]				

2. List all wages, salaries, commissions, or contributions to an employee benefit plan owed, showing:

	<u>Name</u>	<u>Address</u>	<u>Amount</u>	<u>Nature</u>	<u>Collateral</u>	<u>Dispute</u>
	[REDACTED]					

3. List all consumer deposits owed, showing:

	<u>Name</u>	<u>Address</u>	<u>Amount</u>	<u>Nature</u>	<u>Collateral</u>	<u>Dispute</u>
	<i>none</i>					

4. List all taxes owed, showing:

	<u>Name</u>	<u>Address</u>	<u>Amount</u>	<u>Nature</u>	<u>Collateral</u>	<u>Dispute</u>
	[REDACTED]					

5. List all unsecured claims, showing:

	<u>Name</u>	<u>Address</u>	<u>Amount</u>	<u>Nature</u>	<u>Collateral</u>	<u>Dispute</u>
	<i>See Schedule 5</i>					

6. List all owners or shareholders, showing:

	<u>Name</u>	<u>Address</u>	<u>Ownership %</u>
	<i>None known to be a creditor</i>		

7. List all applicable regulatory agencies, showing:

	<u>Name</u>	<u>Address</u>
	<i>None known to be a creditor</i>	

DWT 21116223v1 0096943-000002

SCHEDULE B - LIST OF PROPERTY

List each category of property and for each give approximate value obtainable for the asset on the date of assignment/appointment of the receiver, and address where asset is located.

I. Nonexempt Property

Description and Location:

Estimated Liquidation Value on Date of  
Appointment of Receiver:


*unknown*

1. Legal Description and street address of real property, including leasehold interests:

*none*

Tax Parcel Number: *na*

Address: *na*

2. Fixtures: *none*  
3. Cash and bank accounts:   
4. Inventory: *none*  
5. Accounts receivable: *none*  
6. Equipment: *none*  
7. Prepaid expenses, including deposits, insurance, rents, and utilities: *none*  
8. Other, including loans to third parties, claims, and choses in action: *See Schedules 8a and 8b.*

II. Exempt Property

Description and Location:


Estimated Liquidation Value on Date of  
Appointment of Receiver:

*None*


*na*

I DECLARE under penalty of perjury that the foregoing is true, correct, and complete to the best of my knowledge.

DATED this \_\_\_\_ day of \_\_\_\_\_, at \_\_\_\_\_, State of \_\_\_\_\_



Pontard Pharmaceuticals  
General Assignment Schedule 5





## Schedule 8A

## Patents and Patent Applications

	<u>Patent</u>	<u>Country</u>	<u>Application No. or Registration No. (as applicable)</u>	<u>Application Filing Date or Registration Date (as applicable)</u>
	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	US	60/857,067	11/6/2006
	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	US	60/877,515	12/28/2006
	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	US	60/927,347	5/3/2007
	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	US	60/931,309	5/22/2007
	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	US	60/969,441	8/31/2007
	USE OF PICOPLATIN TO TREAT SMALL CELL LUNG CANCER	US	12/508,392	7/23/2009
	A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER	US	60/857,017	11/6/2006
	A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER	US	60/857,564	11/8/2006
	A METHOD OF TREATMENT OF HORMONE-RESISTANT PROSTATE CANCER	US	60/877,570	12/28/2006
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	US	60/889,179	2/9/2007
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	US	60/890,950	2/21/2007
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	US	60/931,609	5/24/2007
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	US	60/952,440	7/27/2007
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	US	11/935,979	11/6/2007
	A METHOD OF TREATMENT OF COLORECTAL CANCER	US	60/857,066	11/6/2006

	Patent	Country	Application No. or Registration No. (as applicable)	Application Filing Date or Registration Date (as applicable)
	A METHOD OF TREATMENT OF COLORECTAL CANCER	US	60/857,725	11/8/2006
	A METHOD OF TREATMENT OF COLORECTAL CANCER	US	60/877,495	12/28/2006
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	US	60/889,191	2/9/2007
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	US	60/931,589	5/24/2007
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	US	60/683,852	10/30/2007
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	US	12/367,394	2/6/2009
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	US	12/464,662	5/12/2009
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	US	12/465,563	5/13/2009
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	US	12/508,372	7/23/2009
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	PCT	PCT/US2010/34593	5/12/2010
	USE OF PICOPLATIN TO TREAT COLORECTAL CANCER	US	13/319,852	11/10/2011
	ENCAPSULATED PICOPLATIN	US	60/889,201	2/9/2007
	ENCAPSULATED PICOPLATIN	US	60/889,675	2/13/2007
	ENCAPSULATED PICOPLATIN	US	60/984,156	10/31/2007
	ENCAPSULATED PICOPLATIN	US	60/989,020	11/19/2007
	ENCAPSULATED	PCT	PCT/US2008/00174	2/8/2009

	<u>Patent</u>	<u>Country</u>	<u>Application No. or Registration No. (as applicable)</u>	<u>Application Filing Date or Registration Date (as applicable)</u>
	PICOPLATIN		6	
	ENCAPSULATED PICOPLATIN	US	12/536,311	8/5/2009
	ENCAPSULATED PICOPLATIN	AU	2008214199	2/8/2008
	ENCAPSULATED PICOPLATIN	BR	PI 0806362-1	2/8/2008
	ENCAPSULATED PICOPLATIN	CA	2,677,639	2/8/2008
	ENCAPSULATED PICOPLATIN	CN	200880011347.9	2/8/2008
	ENCAPSULATED PICOPLATIN	EG	1200/2009	2/8/2008
	ENCAPSULATED PICOPLATIN	EP	08725387.8	2/8/2008
	ENCAPSULATED PICOPLATIN	HK	10102719.4	2/8/2008
	ENCAPSULATED PICOPLATIN	ID	W-00200902208	2/8/2008
	ENCAPSULATED PICOPLATIN	IL	200261	2/8/2008
	ENCAPSULATED PICOPLATIN	IN	5257/CHENP/2009	2/8/2008
	ENCAPSULATED PICOPLATIN	JP	2009-549126	2/8/2008
	ENCAPSULATED PICOPLATIN	KR	10-2009-7018781	2/8/2008
	ENCAPSULATED PICOPLATIN	MX	MX/s/2009/008487	2/8/2008
	ENCAPSULATED PICOPLATIN	PH	1-2009-501520	2/8/2008
	ENCAPSULATED PICOPLATIN	RU	2009133447	2/8/2008
	ENCAPSULATED PICOPLATIN	UA	200909261	2/8/2008
	ENCAPSULATED PICOPLATIN	VN	1-2009-01904	2/8/2008
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	US	60/889,171	2/9/2007
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	US	60/889,681	2/13/2007
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	PCT	PCT/US2008/00175 2	2/8/2008
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	US	12/536,335	8/5/2009

\* co-owned with Genzyme Corporation

	<u>Patent</u>	<u>Country</u>	<u>Application No. or Registration No. (as applicable)</u>	<u>Application Filing Date or Registration Date (as applicable)</u>
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	AU	2008214202	2/8/2008
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	BR	0806418-0	2/8/2008
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	CA	2,677,640	2/8/2008
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	CN	200880011357.2	2/8/2008
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	EG	1201/2009	2/8/2008
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	EP	08725393.6	2/8/2008
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	HK	10106157.4	2/8/2008
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	ID	W-00200902207	2/8/2008
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	IL	200262	2/8/2008
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	IN	5256/CHENP/2009	2/8/2008
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	JP	2009-549128	2/8/2008
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	KR	10-2009-7018780	2/8/208
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	MX	MX/a/2009/008488	2/8/2008
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	PH	1-2009-501521	2/8/2008
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	RU	2009133446	2/8/2008
	STABILIZED PICOPLATIN ORAL DOSAGE FORM*	UA	200909262	2/8/2008
	STABILIZED PICOPLATIN ORAL DOSAGE FORM AND	VN	1-2009-01903	2/8/2008

\*co-owned with Genzyme Corporation

Schedule 8A  
Page 4 of 10

	<u>Patent</u>	<u>Country</u>	<u>Application No. or Registration No. (as applicable)</u>	<u>Application Filing Date or Registration Date (as applicable)</u>
	PROCESS FOR PREPARING THE SAME*			
	STABILIZED INTRAVENOUS DOSAGE FORM	US	60/949,639	6/27/2007
	ORAL FORMULATION FOR PICOPLATIN	US	60/950,033	7/16/2007
	ORAL FORMULATION FOR PICOPLATIN	US	61/043,962	4/10/2008
	ORAL FORMULATION FOR PICOPLATIN	PCT	PCT/US2008/00866 9	7/16/2008
	ORAL FORMULATION FOR PICOPLATIN	US	12/669,274	1/15/2010
	ORAL FORMULATION FOR PICOPLATIN	CA	2,693,057	7/16/2008
	ORAL FORMULATION FOR PICOPLATIN	CN	200880103323.6	7/16/2008
	ORAL FORMULATION FOR PICOPLATIN	EP	08780206.2	7/16/2008
	ORAL FORMULATION FOR PICOPLATIN	HK	11101572.1	7/16/2008
	ORAL FORMULATION FOR PICOPLATIN	JP	2010-517010	7/16/2008
	ORAL FORMULATION FOR PICOPLATIN	TW	097127053	7/16/2008
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	US	61/027,387	2/8/2008
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	PCT	PCT/US2009/00077 0	2/6/2009
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	US	12/866,702	11/11/2010
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	AU	2009210654	2/6/2009
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	CA	2,715,348	2/6/2009

\*co-owned with Genzyme Corporation

Schedule 8A  
Page 5 of 10

	<u>Patent</u>	<u>Country</u>	Application No. or Registration No. (as applicable)	Application Filing Date or Registration Date (as applicable)
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	CN	200980109758.6	2/6/2009
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	EP	09708527.8	2/6/2009
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	HK	11109428.0	2/6/2009
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	JP	2010-545883	2/6/2009
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	US	61/027,382	2/8/2008
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	PCT	PCT/US2009/00077 3	2/6/2009
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	US	12/866,706	11/15/2010
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	AU	2009210656	2/6/2009
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	CA	2,715,353	2/6/2009
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	CN	200980111015.2	2/6/2009
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	EP	09708387.7	2/6/2009
	USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER	HK	11109425.3	2/6/2009
	USE OF PICOPLATIN	JP	2010-545885	2/6/2009

	Patent	Country	Application No. or Registration No. (as applicable)	Application Filing Date or Registration Date (as applicable)
	AND CETUXIMAB TO TREAT COLORECTAL CANCER			
	USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER	US	61/027,360	2/8/2008
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	PCT	PCT/US2009/00075 0	2/6/2009
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	US	12/866,710	11/10/2010
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	AU	2009210734	2/6/2009
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	CA	2,715,329	2/6/2009
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	CN	200980110139.9	2/6/2009
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	EP	09708292.9	2/6/2009
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	HK	11109534.1	2/6/2009
	PICOPLATIN AND AMRUBICIN TO TREAT LUNG CANCER	JP	2010-545878	2/6/2009
	COMBINATION CHEMOTHERAPY COMPRISING STABILIZED INTRAVENOUS PICOPLATIN DOSAGE FORM	US	61/027,388	2/8/2008
	COMBINATION CHEMOTHERAPY COMPRISING STABILIZED INTRAVENOUS PICOPLATIN DOSAGE FORM	US	61/055/071	5/21/2008
	STABILIZED PICOPLATIN DOSAGE FORM	PCT	PCT/US2008/08076	6/27/2008
	STABILIZED PICOPLATIN DOSAGE FORM	US	12/635,517	12/10/2009
	COMBINATION	US	12/635,534	12/10/2009

Schedule 8A  
Page 7 of 10

	<u>Patent</u>	<u>Country</u>	<u>Application No. or Registration No. (as applicable)</u>	<u>Application Filing Date or Registration Date (as applicable)</u>
	THERAPY FOR OVARIAN CANCER			
	COMBINATION THERAPY FOR OVARIAN CANCER	US	12/781,599	5/17/2010
	COMBINATION THERAPY FOR OVARIAN CANCER	PCT	PCT/US11/036855	5/17/2011
	STABILIZED PICOPLATIN DOSAGE FORM	AU	2008295576	6/27/2008
	STABILIZED PICOPLATIN DOSAGE FORM	BR	PI0811816-7	6/27/2008
	STABILIZED PICOPLATIN DOSAGE FORM	CA	2,691,115	6/27/2008
	STABILIZED PICOPLATIN DOSAGE FORM	CN	200880022248.0	6/27/2008
	STABILIZED PICOPLATIN DOSAGE FORM	EP	08828991.3	6/27/2008
	STABILIZED PICOPLATIN DOSAGE FORM	HK	10108170.3	6/27/2008
	STABILIZED PICOPLATIN DOSAGE FORM	ID	W-00201000277	6/27/2008
	STABILIZED PICOPLATIN DOSAGE FORM	IL		6/27/2008
	STABILIZED PICOPLATIN DOSAGE FORM	IN	7725/CHENP/2009	6/27/2008
	STABILIZED PICOPLATIN DOSAGE FORM	JP	2010-514837	6/27/2008
	STABILIZED PICOPLATIN DOSAGE FORM	KR	10-2010-7001745	6/27/2008
	STABILIZED PICOPLATIN DOSAGE FORM	MX	MX/a/2009/013835	6/27/2008
	STABILIZED PICOPLATIN DOSAGE FORM	RU	2010102096	6/27/2008
	STABILIZED PICOPLATIN DOSAGE FORM	TW	097124033	6/28/2008
	STABILIZED PICOPLATIN DOSAGE FORM	UA	201000817	6/28/2008



	Patent	Country	Application No. or Registration No. (as applicable)	Application Filing Date or Registration Date (as applicable)
	PICOPLATIN ORAL DOSAGE FORM HAVING HIGH BIOAVAILABILITY	US	61/169,679	4/15/2009
	PICOPLATIN ORAL DOSAGE FORM HAVING HIGH BIOAVAILABILITY	US	61/170,487	4/17/2009
	HIGH BIOAVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY	PCT	PCT/US2010/00735	3/11/2010
	HIGH BIOAVAILABILITY ORAL PICOPLATIN ANTI-CANCER THERAPY	US	13/264,343	10/13/2011
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	US	61/177,567	5/12/2009
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	PCT	PCT/US2010/34591	5/12/2010
	USE OF PICOPLATIN TO TREAT PROSTATE CANCER	US	13/319,647	11/9/2011
	USE OF PICOPLATIN AND DOCETAXEL TO TREAT PROSTATE CANCER	US	61/177,571	5/12/2009
	IMPROVED SYNTHESIS OF PICOPLATIN	US	61/186,526	6/12/2009
	IMPROVED SYNTHESIS OF PICOPLATIN	PCT	PCT/US2010/38348	6/11/2010
	IMPROVED SYNTHESIS OF PICOPLATIN	TW	099119171	6/11/2010
	METHOD TO TREAT SMALL CELL LUNG CANCER	US	61/311,169	3/5/2010
	METHOD TO TREAT SMALL CELL LUNG CANCER	US	61/345,442	5/17/2010
	METHOD TO TREAT SMALL CELL LUNG CANCER	PCT	PCT/US2011/02726 4	3/4/2011
	METHOD TO TREAT SMALL CELL LUNG CANCER	TW	100107612	3/7/2011
	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	US	61/345,451	5/17/2010
	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	US	61/346,777	5/20/2010

	Patent	Country	Application No. or Registration No. (as applicable)	Application Filing Date or Registration Date (as applicable)
	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	PCT	PCT/US2011/02726 8	3/4/2011
	COMBINATION THERAPY FOR SMALL CELL LUNG CANCER	TW	100107621	3/7/2011
	INHIBITORS OF FOCAL ADHESION KINASE	PCT	PCT/US2008/00320	3/10/2008
	INHIBITORS OF FOCAL ADHESION KINASE	US	12/531,010	9/11/2009
	INHIBITORS OF FOCAL ADHESION KINASE	CA	2,681,015	3/10/2008
	INHIBITORS OF FOCAL ADHESION KINASE	CN	200880015910.X	3/10/2008
	INHIBITORS OF FOCAL ADHESION KINASE	EP	08726698.7	3/10/2008
	INHIBITORS OF FOCAL ADHESION KINASE	HK	10107956.5	3/10/2008
	INHIBITORS OF FOCAL ADHESION KINASE	IN	5948/DELNP/2009	3/10/2008
	INHIBITORS OF FOCAL ADHESION KINASE	JP	2009-553600	3/10/2008
	INHIBITORS OF FOCAL ADHESION KINASE	TW	97109125	3/14/2008
	METHODS OF PROMOTING APOPTOSIS AND INHIBITING METASTASIS	PCT	PCT/US2010/04535	8/12/2010
	SYNTHESIS AND USE OF KINASE INHIBITORS	US	61/359,942	6/30/2010
	SYNTHESIS AND USE OF KINASE INHIBITORS	PCT	PCT/US2011/04216	6/28/2011
	ORAL FORMULATION OF KINASE INHIBITORS	US	61/359,694	6/29/2010
	ORAL FORMULATION OF KINASE INHIBITORS	PCT	PCT/US2011/04216	6/28/2011

Schedule 8B  
Trademarks

	<u>Trademarks</u>	<u>Country</u>	<u>Serial No.</u>	<u>Registration No.</u>
	PONIARD	US	77/926,443	
	PONIARD	EUROPE	5136247	5136247
	PONIARD	BULGARIA	87794	64215
	PONIARD	CANADA	1,305,719	
	PONIARD	CHINA	5420788	5420788
	PONIARD	JAPAN	2006-55411	5011442
	PONIARD	MEXICO	788572	953650
	PONIARD	ROMANIA	M2006-06634	078934
	PONIARD	RUSSIA	2006716360	334572
	PONIARD	UKRAINE	M200608493	83816
	PONIARD	US	78/941,640	3,247,488
	PONIARD	EUROPE	5646484	5646484
	PONIARD	CANADA	1,332,920	
	PONIARD	CHINA	5875890	5875890
	PONIARD	INDIA	1526598	
	PONIARD	JAPAN	20076424	5051753
	PONIARD	MEXICO	832693	1013834
	PONIARD	RUSSIA	2007701832	351832
	PONIARD	UKRAINE	M200701043	92279
	P DESIGN	EUROPE	5645965	5645965
	P DESIGN	CANADA	1,332,922	

	P DESIGN	CHINA	5875888	5875888
	<u>Trademarks</u>	<u>Country</u>	<u>Serial No.</u>	<u>Registration No.</u>
	P DESIGN	INDIA	1526599	
	P DESIGN	JAPAN	20075966	5051751
	P DESIGN	MEXICO	832691	983191
	P DESIGN	RUSSIA	2007701837	342645
	P DESIGN	UKRAINE	M200701044	93525
	P DESIGN	US	78/941,637	3,247,487
	P DESIGN	CHINA	5875889	5875889
	P DESIGN	MEXICO	832692	1013833
	P DESIGN	RUSSIA	2007702270	350589
	P PONIARD & DESIGN (LOGO)	US	78/941,528	3,247,481
	P DESIGN	CROATIA	Z20070832A	Z20070832
	P DESIGN	SERBIA	Z9912007	55571
	PONIARD	CROATIA	Z20070831A	Z20070831
	PONIARD	SERBIA	Z9922007	55553

Schedule 8B  
Page 2 of 2